Prenalterol: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Prenalterol.svg|Prenalterol | |||
File:Prenalterol_synthesis.svg|Prenalterol synthesis | |||
</gallery> | |||
Latest revision as of 01:55, 17 February 2025
Prenalterol is a cardiac stimulant that functions as a beta-1 adrenergic receptor agonist. It was developed in the 1980s as a treatment for heart failure and angina pectoris, but its use has been limited due to the risk of tachycardia.
Pharmacology[edit]
Prenalterol works by stimulating the beta-1 adrenergic receptors in the heart, which increases cardiac output and decreases systemic vascular resistance. This results in improved blood flow and reduced symptoms of heart failure and angina.
Clinical Use[edit]
Prenalterol has been used in the treatment of heart failure and angina pectoris. However, its use has been limited due to the risk of tachycardia, a condition characterized by an abnormally fast heart rate.
Side Effects[edit]
The most common side effect of prenalterol is tachycardia. Other potential side effects include palpitations, chest pain, and dizziness. In rare cases, prenalterol can cause cardiac arrhythmia, a serious condition that can lead to cardiac arrest.
History[edit]
Prenalterol was developed in the 1980s as a potential treatment for heart failure and angina pectoris. However, its use has been limited due to the risk of tachycardia.
See Also[edit]
-
Prenalterol
-
Prenalterol synthesis